-+ 0.00%
-+ 0.00%
-+ 0.00%
AbbVie, DISCO Pharmaceuticals Team Up On AND-Gated Bispecific Solid Tumor Therapeutics Using DISCOtech Platform; Deal Carries $40M Upfront, Up To $2.5B Milestones
Share
Listen to the news
  • The collaboration leverages DISCO’s proprietary DISCOtech® surfaceome mapping platform and AND-gated bispecific discovery approach together with AbbVie’s global oncology research and development expertise to identify and potentially advance highly selective AND-gated bispecific therapeutics.
  • Upon successful completion of specified research activities by DISCO, AbbVie will have the option to exclusively license selected programs for further development.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending